KYT-0353   Click here for help

GtoPdb Ligand ID: 9347

Synonyms: COMPOUND-JP [US20160279103] [1] | JPH-203 | JPH203 | KYT0353
Compound class: Synthetic organic
Comment: KYT-0353 (JPH203) is a potent and selective inhibitor of L-type amino acid transporter 1 (SLC7A5) [2], that is being investigated as an anti-cancer agent. Structurally it is a tyrosine analog.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 3
Rotatable bonds 7
Topological polar surface area 124.6
Molecular weight 471.08
XLogP 1.81
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES OC(=O)C(Cc1cc(Cl)c(c(c1)Cl)OCc1cc(N)cc2c1oc(n2)c1ccccc1)N
Isomeric SMILES OC(=O)[C@H](Cc1cc(Cl)c(c(c1)Cl)OCc1cc(N)cc2c1oc(n2)c1ccccc1)N
InChI InChI=1S/C23H19Cl2N3O4/c24-16-6-12(8-18(27)23(29)30)7-17(25)21(16)31-11-14-9-15(26)10-19-20(14)32-22(28-19)13-4-2-1-3-5-13/h1-7,9-10,18H,8,11,26-27H2,(H,29,30)/t18-/m0/s1
InChI Key XNRZJPQTMQZBCE-SFHVURJKSA-N
No information available.
Summary of Clinical Use Click here for help
JPH203 has progressed to clinical evaluation in Japan, to determine efficacy in advanced biliary tract cancers (Randomized Controlled Phase 2 Clinical Trial of JPH203 in Patients With Advanced Biliary Tract Cancers).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Many tumors overexpress LAT1, a transporter for uptake of branched-chain (valine, isoleucine, and leucine) and neutral aromatic side-chain (phenylalanine and tyrosine) amino acids. Tumour cells have a high demand for nutrients, including amino acids, so targeting amino acid transporters is considered a valid strategy for developing novel cancer therapuetics. The restricted nature of LAT1 expression suggests it is a target with potential to minimise damage to normal cells and tissues.